Adalimumab vs Etanercept in Quality of Life Improvement
Adalimumab showed a slightly higher reduction in PASI after 1 year, however it proved an equivalent efficacy to Etanercept after an extensive follow-up (up to 5 years) Contrarily to etanercept, adalimumab patients showed a progressive improvement with DLQI (84 to 77) For both groups, sustained response (PASI75 maintenance of results 60 months after initiation of…